KT&G Launches ESSE Himalaya Winter with Advanced Flavor-reducing Technology

Innovation by 2FIRSTS.ai
May.28.2024
KT&G Launches ESSE Himalaya Winter with Advanced Flavor-reducing Technology
ENewsToday reported on May 27 that "ESSE Himalaya Winter" features tobacco from the Himalayas and Cold Locking Tech.

According to ENewsToday on May 27th, the new series "ESSE Himalaya Winter" stands out for its use of tobacco leaves from the Himalayas and Cold Locking Tech. In addition, the product enhances the reduction of tobacco smell in the mouth after smoking by utilizing advanced flavor-reducing technology.

 

KT&G Launches ESSE Himalaya Winter with Advanced Flavor-reducing Technology

 

The packaging design of this product incorporates a navy blue color with black and features an image of the Himalayan mountain range to emphasize the scent and image of "ESSE Himalaya Winter". The tar and nicotine content of "ESSE Himalaya Winter" are 1.0mg and 0.10mg respectively, and it is priced at 4500 Korean won (approximately $3.30) per pack.

 

"ESSE Himalaya Winter" is the first extension product of KT&G's "ESSE Himalaya" series to apply flavor reduction technology. Since its initial launch in South Korea in 2019, the series has rapidly gained popularity, with sales of approximately 10 million packs within four months of its release. This has paved the way for a new trend in reducing the smell of tobacco.

 

Song Seung-Cheol, head of the ESSE team at KT&G, stated, "ESSE Himalaya Winter not only enhances the natural aroma of tobacco leaves from clean regions such as the Himalayas, but also improves the effectiveness of reducing tobacco odor through KT&G's unique technology.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Six Years of Data Show FDA Clearing PMTA Backlog
Six Years of Data Show FDA Clearing PMTA Backlog
FDA data from FY2020 to FY2025 show how the PMTA system for e-cigarette products evolved after an early surge of submissions created prolonged front-end delays. Millions of applications accumulated at the Acceptance stage before entering substantive review. Since 2023, the number of applications pending acceptance has declined sharply, and industry participants report shorter initial decision timelines in late 2025.
Feb.06
Special Report | New Patents Show China Tobacco Hubei Industrial Testing Gas-Releasing Nicotine Pouches
Special Report | New Patents Show China Tobacco Hubei Industrial Testing Gas-Releasing Nicotine Pouches
Newly published patent filings indicate that China Tobacco Hubei Industrial Co., Ltd., a subsidiary of China National Tobacco Corporation (CNTC), is exploring nicotine pouch technologies capable of releasing gas during oral use. The designs include carbon-dioxide microcapsules that burst in the mouth and effervescent systems that generate gas through chemical reactions with saliva, suggesting efforts to introduce new sensory dynamics into modern oral nicotine products.
News
Mar.04
SICPA Secures Five-Year UK Vape Tax Stamp Contract
SICPA Secures Five-Year UK Vape Tax Stamp Contract
HM Revenue and Customs (HMRC) has awarded a five-year contract to Swiss technology company SICPA and Cartor Security Printers to implement the United Kingdom’s new vaping duty stamp and track-and-trace system, beginning in April 2026.
Market
Feb.24
Russia’s Duma Deputy Speaker Davankov calls for a total vape ban, citing drug sales disguised as vapes
Russia’s Duma Deputy Speaker Davankov calls for a total vape ban, citing drug sales disguised as vapes
Vladislav Davankov, deputy speaker of Russia’s State Duma, urged a nationwide ban on vapes, arguing it would help prevent drugs being sold under the cover of vaping products, including near schools. The remarks come as Russia prepares to enforce a separate ban on vape sales at public transport stops starting Sept. 1, 2026.
Feb.09 by 2FIRSTS.ai
Special Report | Belarus Rejects Vape Ban, Opts for Tighter Market Controls
Special Report | Belarus Rejects Vape Ban, Opts for Tighter Market Controls
After weeks of debate over a potential blanket prohibition, Belarus has decided against banning electronic cigarettes, choosing instead to tighten control over wholesale, imports and licensing. President Alexander Lukashenko warned that an outright ban could drive the market underground and undermine state revenues, as officials move to curb widespread illicit trade while keeping retail sales largely intact.
Mar.04
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24